GSK plc (NYSE:GSK) Q1 2023 Earnings Call Transcript
Nick Stone: This is the usual Safe Harbor statement. We will comment on our performance using constant exchange rates, or CER, unless stated otherwise.
Source: insidermonkey.com
Page 21 - Nick Stone News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nick Stone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nick Stone Today - Breaking & Trending Today
GSK : European Medicines Agency validates marketing authorisation application for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer - Form 6-K
European Medicines Agency validates marketing authorisation application for Jemperli plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer ... | April 25, 2023
Source: marketscreener.com
Investegate |Braemar PLC Announcements | Braemar PLC: Results of General Meeting
Investegate announcements from Braemar PLC, Results of General Meeting
Source: investegate.co.uk
BELLUS Health Inc.: GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough
Source: finanznachrichten.de
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with... | March 30, 2023
Source: marketscreener.com